May 29 |
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
|
May 15 |
Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02
|
May 14 |
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
|
Apr 19 |
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
|
Apr 18 |
Enliven Therapeutics files to sell 6.43M shares for holders
|
Apr 11 |
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
|
Apr 11 |
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
|
Apr 9 |
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
|
Apr 9 |
Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),
|
Mar 28 |
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
|